Amid active import substitution and the harmonization of legislation with international norms, the field of medical device testing is experiencing tectonic shifts. Market experts note that technical, toxicological, and clinical tests can no longer be viewed as separate stages — they now form a single, continuous cycle for confirming product safety and efficacy.
Toxicology: A Move Toward Alternative Methods
The most significant changes have affected toxicological (biological) studies. Following the global trend, Russian regulators and testing laboratories are actively implementing the 3R principles (Replacement, Reduction, Refinement of animal testing).
According to the updated GOST standards of the ISO 10993 series, priority in biocompatibility assessment is given to the physical and chemical analysis of materials. If the device composition is fully chemically characterized and the data indicate no risks, a significant portion of in vivo tests can be replaced with modeling or in vitro tests.
Key point: Updated pyrogenicity assessment methods using the Monocyte Activation Test (MAT) have come into force, making it possible to stop using rabbits for bacterial endotoxin testing for a wide range of implantable devices.
Technical Testing: “Digital Twin” Instead of Physical Experiments
In the field of technical testing, the risk analysis methodology is coming to the forefront. Laboratories are no longer limited to “failure” checks for pressure or tension. Now, clients are required to provide validated computer models and simulations.
The introduction of mathematical modeling makes it possible to predict the behavior of an endoprosthesis or pacemaker under load over the long term even before a physical prototype is created. This is particularly relevant for high-tech Class 3 devices (implants, vascular stents). Experts emphasize that having a verified “digital model” significantly speeds up the expert review process at Roszdravnadzor, as it resolves questions about mechanical reliability at the earliest stages.
Clinical Trials: A Focus on Real-World Practice
A revolution is also taking place in the clinical segment. The regulator is increasingly demanding evidence of efficacy not only under “ideal” hospital conditions but also in routine medical practice. There is a growing demand for Real-World Data.
Furthermore, for solutions involving artificial intelligence (AI-enabled software), unique protocols are being introduced that include testing on retrospective data and strict dataset validation. “A technical error in an algorithm is now classified as an adverse event requiring just as rigorous an investigation as a material defect,” comments a representative from one of the certification bodies.
Analysts’ Summary: The convergence of the three testing areas into a unified safety ecosystem is the main trend of 2026. Manufacturers who invest in in-depth toxicological characterization of materials, advanced mathematical modeling, and post-market data monitoring gain a significant competitive advantage when entering the EAEU market.
